Last reviewed · How we verify
Interferon-beta-1a FBS-free/HSA-free
Interferon-beta-1a activates interferon-alpha/beta receptors on immune cells to enhance antiviral and immunomodulatory responses.
Interferon-beta-1a activates interferon-alpha/beta receptors on immune cells to enhance antiviral and immunomodulatory responses. Used for Multiple sclerosis (relapsing-remitting form), Relapsing forms of multiple sclerosis.
At a glance
| Generic name | Interferon-beta-1a FBS-free/HSA-free |
|---|---|
| Sponsor | EMD Serono |
| Drug class | Interferon |
| Target | Interferon-alpha/beta receptor (IFNAR) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interferon-beta-1a is a recombinant cytokine that binds to type I interferon receptors (IFNAR1/IFNAR2) on the surface of immune and other cells, triggering intracellular signaling cascades that increase expression of antiviral proteins, enhance natural killer cell activity, and modulate T-cell responses. The FBS-free/HSA-free formulation removes animal-derived serum components and human serum albumin, improving manufacturing consistency and reducing potential immunogenic contaminants while maintaining the same biological activity as standard interferon-beta-1a.
Approved indications
- Multiple sclerosis (relapsing-remitting form)
- Relapsing forms of multiple sclerosis
Common side effects
- Flu-like symptoms (fever, chills, myalgia)
- Injection site reactions
- Headache
- Fatigue
- Depression/mood changes
- Elevated liver enzymes
- Leukopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon-beta-1a FBS-free/HSA-free CI brief — competitive landscape report
- Interferon-beta-1a FBS-free/HSA-free updates RSS · CI watch RSS
- EMD Serono portfolio CI